Kusum pharma assesses destroyed Ukrainian Sumy plant, shifts supply to India
Pharmaceutical company Kusum is calculating the losses from the destruction of its plant in Sumy by the aggressor and is preparing to supply medicines from its manufacturing facilities in India.
Pharmaceutical giant Kusum is assessing the damage caused by the aggressor's destruction of its Sumy plant in Ukraine and is now gearing up to meet the demand for medicines from its Indian manufacturing units. The company has not yet finalized the extent of losses incurred at the Sumy plant, as some stock of medicines remain in warehouses, but the duration of their effectiveness remains uncertain. Kusum informed Interfax-Ukraine that production is currently being reallocated among its Indian manufacturing facilities.
Should no regulatory obstacles arise, Kusum is poised to resume production of the medicines originally manufactured in Sumy. The company also confirmed that its Indian production adheres to European Good Manufacturing Practice (GMP) standards, and its plants hold regulatory accreditation in 22 countries worldwide. Reports indicate that the aggressor inflicted damage on Kusum's pharmaceutical plant in Sumy on Wednesday. Kusum, ranked among the top 10 pharmaceutical companies in Ukraine, is actively addressing the crisis.
Written by urgent.news from Interfax-Ukraine's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
